rights to the biomarker panel.
Ovarian Cancer Diagnostic Test Progress
-- Received the distinguished Society for Gynecologic Oncologists' (SGO)
Basic Science Poster Award for its abstract, "Prospective independent
validation of a marker panel for distinguishing benign from malignant
pelvic masses." The abstract, which demonstrated that the Company's
Ovarian Tumor Triage Test correctly identified 84 percent of ovarian
cancer cases, compared to only 33 percent identified using standard
diagnosis methods without the test, was presented at the SGO 38th
Annual Meeting on Women's Cancer last year in San Diego.
-- Completed enrollment of 550 patients at 27 medical centers in a
clinical trial to evaluate Vermillion's Ovarian Tumor Triage Test to
differentiate women with ovarian cancer from women with benign pelvic
-- Presented seven studies at the European Society for Gynecologic
Oncology meeting describing advancements in Vermillion's ovarian cancer
-- Data showed that Vermillion's panel of ovarian cancer protein
biomarkers in combination with CA-125 could more accurately identify
early-stage ovarian cancer than could CA-125 alone.
-- Data demonstrated that Vermillion's ovarian cancer biomarker panel
could accurately and with statistical significance predict women with
ovarian cancer who had good prognosis from those who did not. The study
used Kaplan-Meier analysis to show that women with a low panel score
were significantly more likely to survive than women with high scores,
independent of the stage of the disease.
-- Renewed a long-standing collaboration with Johns Hopkins University on
the development of novel biomarkers that can be applied towar
|SOURCE Vermillion, Inc.|
Copyright©2008 PR Newswire.
All rights reserved